Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
株式のランク #660
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
株価
$17.64
時価総額
$32.65B
変化(1日)
-3.24%
変化(1年)
-23.70%
JP
取引 Daiichi Sankyo Company, Limited (DSNKY)

カテゴリー

Daiichi Sankyo Company, Limited(DSNKY)の利益
Dec 2025 時点の利益 TTM: $2.25B
Daiichi Sankyo Company, Limited の最新の財務報告によると、同社の現在の利益は $2.25B です。2024 年には $1.57B の利益を上げ、これは 2023 年の利益 $955.41M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Daiichi Sankyo Company, Limited の利益の推移(2000 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $2.25B -5.02%
2025 $2.37B 51.37%
2024 $1.57B 64.05%
2023 $955.41M 58.24%
2022 $603.78M -9.78%
2021 $669.24M -49.03%
2020 $1.31B 69.80%
2019 $773.25M 1.40%
2018 $762.56M -3.25%
2017 $788.16M -27.54%
2016 $1.09B 63.21%
2015 $666.47M -31.10%
2014 $967.36M -1.02%
2013 $977.31M 139.07%
2012 $408.79M -71.86%
2011 $1.45B 39.41%
2010 $1.04B -133.26%
2009 $-3.13B -287.21%
2008 $1.67B 55.54%
2007 $1.08B -7.55%
2006 $1.16B 60.36%
2005 $725.65M -8.51%
2004 $793.11M 29.61%
2003 $611.93M 0.45%
2002 $609.17M -8.18%
2001 $663.43M -26.55%
2000 $903.21M 0.00%
同業他社の利益
企業 利益 利益の差
$25.73B 1,041.79%
US
$12.40B 450.35%
GB
$32.58B 1,345.82%
US
$6.60B 192.75%
US
$16.35B 625.63%
CH